Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price has languished in 2024 while the market has flourished.

During the period, the biotechnology giant's shares have lost approximately 3% of their value.

This compares unfavourably to the performance of the ASX 200 index, which is up over 10% year to date. And that excludes the dividends paid over the period, which add somewhere in the region of 4%.

Perhaps the most disappointing part of this is that over the past couple of decades, the CSL share price has built a reputation of being a market-beater.

But we just simply have not seen this since the pandemic for a number of reasons. Since late 2019, CSL's shares have gone sideways.

But those lost years could be a thing of the past in the near future with analysts tipping CSL to find its way again.

A group of men in the office celebrate after winning big.

Image source: Getty Images

CSL share price tipped to rise strongly

According to a recent note out of Bell Potter, its analysts believe that the company is about to embark on a journey of strong and consistent growth.

In light of this, its analysts feel that the CSL share price is now being undervalued by the market.

Commenting on why it thinks now could be a good time to invest in the company, the broker said:

CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

In our view the stock looks undervalued on a PE ratio 18%/8% below 5yr/10yr historical averages and is set for double-digit earnings growth driven by the core Behring division.

The note reveals that Bell Potter has a buy rating and $345.00 price target on CSL's shares. Based on its current share price of $280.74, this implies potential upside of almost 17% for investors over the next 12 months.

To put this into context, a $5,000 investment in the company would turn into approximately $5,800 by this time next year if Bell Potter is on the money with its recommendation.

Overall, this could make CSL a great option for investors that are wanting to add some high-quality stocks to their portfolio for 2025.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »